Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT02149199
Registration number
NCT02149199
Ethics application status
Date submitted
16/05/2014
Date registered
29/05/2014
Date last updated
15/11/2019
Titles & IDs
Public title
A Clinical Study to Evaluate Symbicort Turbuhaler Used 'as Needed' in Adults and Adolescents With Asthma.
Query!
Scientific title
A Clinical Study Comparing Symbicort® 'as Needed' With Terbutaline 'as Needed' and With Pulmicort® Twice Daily Plus Terbutaline 'as Needed' in Adult and Adolescent Patients With Asthma.
Query!
Secondary ID [1]
0
0
2013-004474-96
Query!
Secondary ID [2]
0
0
D589SC00001
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
SYGMA1
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Asthma
0
0
Query!
Condition category
Condition code
Respiratory
0
0
0
0
Query!
Asthma
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - budesonide/formoterol 'as needed' + budesonide placebo bid
Treatment: Drugs - terbutaline 'as needed' + placebo budesonide bid
Treatment: Drugs - budesonide bid + terbutaline 'as needed'
Experimental: Symbicort "as needed"+placebo Pulmicort bid - Symbicort (budesonide/formoterol) Turbuhaler 160/4.5 µg 'as needed' + Placebo Pulmicort Turbuhaler 200 µg bid
Active comparator: terbutaline "as needed"+placebo Pulmicort bid - terbutaline Turbuhaler 0.4 mg 'as needed' + placebo Pulmicort 200 µg Turbuhaler bid
Active comparator: Pulmicort bid + terbutaline "as needed" - Pulmicort 200 µg Turbuhaler bid + terbutaline 0.4 mg Turbuhaler 'as needed'
Treatment: Drugs: budesonide/formoterol 'as needed' + budesonide placebo bid
Symbicort (budesonide/ formoterol) 160/4.5 µg powder for inhalation 'as needed' plus Pulmicort placebo 200 µg powder for inhalation, 1 inhalation twice daily (morning and evening), 52-week treatment
Treatment: Drugs: terbutaline 'as needed' + placebo budesonide bid
Terbutaline 0.4 mg powder for inhalation 'as needed' plus placebo Pulmicort (budesonide) 200 µg powder for inhalation, 1 inhalation twice daily (morning and evening), 52-week treatment
Treatment: Drugs: budesonide bid + terbutaline 'as needed'
Pulmicort (budesonide) 200 µg powder for inhalation, 1 inhalation twice daily (morning and evening) plus terbutaline 0.4 mg powder for inhalation 'as needed', 52-week treatment
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
'Well-controlled Asthma Week' - a Derived Binary Variable (Yes/No)
Query!
Assessment method [1]
0
0
A well-controlled asthma week is defined as the fulfilment of both conditions A) and B) below: A) Two or more of the following criteria are fulfilled: - No more than 2 days with a daily asthma symptom score \>1 - No more than 2 days of 'as needed' medication use, up to a maximum of 4 occasions per week (multiple occasions per day should be regarded as separate occasions) - Morning PEF =80% of Predicted Normal every day B) Both of the following criteria are fulfilled: - No nighttime awakenings due to asthma - No additional inhaled and/or systemic glucocorticosteroid treatment due to asthma. The binary variable well-controlled asthma week was derived for each patient and study week. In addition, for each week, the percent of patients with well-controlled asthma week was derived. It is required that the eDiary had to be completed on at least 5 days in a week to be a well-controlled asthma week.
Query!
Timepoint [1]
0
0
Weekly, up to 52 weeks
Query!
Secondary outcome [1]
0
0
Number of Participants Experiencing at Least One Severe Asthma Exacerbation
Query!
Assessment method [1]
0
0
A severe exacerbation is defined as a deterioration of asthma requiring any of the following: use of systemic glucocorticosteroids (GCS) for at least 3 days, inpatient hospitalization, or emergency room visit due to asthma that required systemic steroids
Query!
Timepoint [1]
0
0
Day 1 up to 52 weeks
Query!
Secondary outcome [2]
0
0
Number of Participants Experiencing at Least One Moderate or Severe Asthma Exacerbation
Query!
Assessment method [2]
0
0
A moderate exacerbation is defined as a deterioration of asthma requiring a change in treatment, i.e. initiation of prescribed additional ICS treatment to avoid progression of the worsening of asthma to a severe exacerbation.
A severe exacerbation is defined as a deterioration of asthma requiring any of the following: use of systemic glucocorticosteroids (GCS) for at least 3 days, inpatient hospitalization, or emergency room visit due to asthma that required systemic steroids
Query!
Timepoint [2]
0
0
Day 1 up to 52 weeks
Query!
Secondary outcome [3]
0
0
Average Change From Baseline in Pre-dose Forced Expiratory Volume in 1 Second (FEV1)
Query!
Assessment method [3]
0
0
Overall estimate of FEV1 (mL) pre-bronchodilator change from baseline. Baseline is the measurement at Visit 3 (prior to first dose of Investigational Product) from MMRM (mixed model repeated measures analysis).
Query!
Timepoint [3]
0
0
Study weeks 0,4,16,28,40,52
Query!
Secondary outcome [4]
0
0
Average Change From Baseline in Morning Peak Expiratory Flow (PEF)
Query!
Assessment method [4]
0
0
Morning peak expiratory flow (eDiary) change from baseline over the randomised treatment period. Baseline is defined as the mean of all non-missing morning measurements during the last 10 days of the run-in period.
Query!
Timepoint [4]
0
0
up to 52 weeks
Query!
Secondary outcome [5]
0
0
Average Change From Baseline in Evening PEF
Query!
Assessment method [5]
0
0
Evening peak expiratory flow (eDiary) change from baseline during the randomised treatment period. Baseline is defined as the mean of all non-missing evening measurements during the last 10 days of the run-in period.
Query!
Timepoint [5]
0
0
up to 52 weeks
Query!
Secondary outcome [6]
0
0
Average Change From Baseline in Number of Inhalations of 'as Needed' Medication.
Query!
Assessment method [6]
0
0
'As needed' inhalations change from baseline over the randomised treatment period. Baseline is defined as the last 10 days of the run-in period. 'As needed' use was calculated as the cumulative doses of 'as needed' medication over the randomised treatment period divided by the follow-up time (number of days - 1). ie, average number of inhalations per day.
Query!
Timepoint [6]
0
0
up to 52 weeks
Query!
Secondary outcome [7]
0
0
Average Change From Baseline in Asthma Symptom Score
Query!
Assessment method [7]
0
0
Asthma symptom score (eDiary) change from baseline during the randomised treatment period. Symptom score is entered morning and evening by the patient on a 4-point scale from 0 to 3 with higher values indicating more severe symptoms. Asthma symptom score is then the sum of the day and night scores, which implies a range of scores from 0 - 6, with higher values indicating more severe symptoms. Baseline is defined as the mean of all non-missing measurements during the last 10 days of the run-in period.
Query!
Timepoint [7]
0
0
up to 52 weeks
Query!
Secondary outcome [8]
0
0
Change From Baseline in the Percentage of Nighttime Awakenings Due to Asthma
Query!
Assessment method [8]
0
0
Night-time awakenings (%) due to asthma change from baseline. Variable analysed is the proportion (%) of nights during the relevant period with night-time awakenings. Baseline refers to the last 10 nights of the run-in period.
Query!
Timepoint [8]
0
0
up to 52 weeks
Query!
Secondary outcome [9]
0
0
Change From Baseline in Percentage of Symptom-free Days
Query!
Assessment method [9]
0
0
Symptom-free days (%) change from baseline during the randomised treatment period.Variable analysed is the proportion (%) of symptom-free days during the relevant period. Baseline refers to the last 10 days of the run-in period.
Query!
Timepoint [9]
0
0
up to 52 weeks
Query!
Secondary outcome [10]
0
0
Change From Baseline in Percentage of 'As Needed' Free Days
Query!
Assessment method [10]
0
0
'As needed' free days (%) change from baseline during the randomised treatment period. An 'as needed' free day is defined as a day and night with no use of 'as needed' medication. Variable analysed is the proportion (%) of 'as needed' free days during the relevant period. Baseline refers to the last 10 days of the run-in period.
Query!
Timepoint [10]
0
0
up to 52 weeks
Query!
Secondary outcome [11]
0
0
Change From Baseline in Percentage of Asthma Control Days
Query!
Assessment method [11]
0
0
Asthma control days (%) change from baseline. An asthma control day is defined as the fulfilment of all of the following criteria; a day and night with no asthma symptoms, a night with no awakenings due to asthma symptoms and a day and night with no use of 'as needed' medication. Variable analysed is the proportion (%) of asthma control days during the randomised treatment period. Baseline refers to the last 10 days of the run-in period.
Query!
Timepoint [11]
0
0
up to 52 weeks
Query!
Secondary outcome [12]
0
0
Number of Patients With Study Specific Asthma Related Discontinuation
Query!
Assessment method [12]
0
0
Study specific asthma related discontinuation
Query!
Timepoint [12]
0
0
up to 52 weeks
Query!
Secondary outcome [13]
0
0
Poorly Controlled Asthma Weeks
Query!
Assessment method [13]
0
0
A poorly-controlled asthma week is defined as a week meeting any one of the following conditions: Two or more consecutive days with awakenings due to asthma on both nights; A recorded use of 'as needed' medication for symptom relief of at least 3 occasions per day, for at least 2 consecutive days; Additional systemic GCS treatment required for severe exacerbation. If there were sufficient data within a week available to confirm the week was not poorly-controlled, the week is labelled as 'does not meet criteria for poorly-controlled'.
Query!
Timepoint [13]
0
0
Weekly for up to 52 weeks
Query!
Secondary outcome [14]
0
0
Number of Participants Experiencing at Least One Occasion With Additional Steroids for Asthma
Query!
Assessment method [14]
0
0
Additional steroids for asthma includes any additional inhaled and/or systemic glucocorticosteroids treatment due to asthma while in the randomised treatment period.
Query!
Timepoint [14]
0
0
Day 1 up to 52 weeks
Query!
Secondary outcome [15]
0
0
Average Change From Baseline in Asthma Control Questionnaire (ACQ-5)
Query!
Assessment method [15]
0
0
Asthma Control Questionnaire 5-item version score change from baseline. ACQ questionnaire contains five questions on patients' symptoms, which are assessed on a 7-point scale from 0 (representing good control) to 6 (representing poor control). The score is the mean score of all questions for which responses are provided.
Query!
Timepoint [15]
0
0
Study weeks 0,4,16,28,40,52
Query!
Secondary outcome [16]
0
0
Average Change From Baseline in Asthma Quality of Life Questionnaire; Standard Version (AQLQ(S))
Query!
Assessment method [16]
0
0
Asthma Quality of Life Questionnaire Standardised Version (AQLQ (S) overall score change from baseline. AQLQ(S) consists of 32 questions in 4 domains. Each question is assessed on a 7-point scale from 1 to 7, with higher values indicating better health-related quality of life. The overall score is calculated as the mean score of all 32 items.
Query!
Timepoint [16]
0
0
Study weeks 0,16,28,40,52
Query!
Secondary outcome [17]
0
0
Percentage of Controller Use Days
Query!
Assessment method [17]
0
0
ICS controller use days (%) during the randomised treatment period is calculated as the cumulative number of days when any controller medication (containing ICS) was taken including maintenance (Pulmicort bid group) and 'as needed' medication (Symbicort 'as needed' group) and additional prescribed ICS for asthma exacerbations and/or long term poor asthma control (all treatment groups), divided by the number of days in the randomised treatment period.
Query!
Timepoint [17]
0
0
up to 52 weeks
Query!
Secondary outcome [18]
0
0
Annual Severe Asthma Exacerbation Rate
Query!
Assessment method [18]
0
0
Severe asthma exacerbations over the randomised treatment period.
Query!
Timepoint [18]
0
0
up to 52 weeks
Query!
Secondary outcome [19]
0
0
Annual Moderate or Severe Asthma Exacerbation Rate
Query!
Assessment method [19]
0
0
Moderate or severe asthma exacerbations during the randomised treatment period.
Query!
Timepoint [19]
0
0
up to 52 weeks
Query!
Eligibility
Key inclusion criteria
INCLUSION CRITERIA 1. Provision of informed consent prior to any study specific procedures. For patients under-age, signed informed consent from both the patient and the patient's parent/legal guardian is required 2. Male or Female, =12 years of age 3. Documented diagnosis of asthma for at least 6 months prior to Visit 1 4. Patients who are in need of Step 2 treatment according to Global Initiative for Asthma guidelines 5. Patients treated with 'as needed' inhaled short-acting bronchodilator(s) only should have pre-bronchodilator Forced Expiratory Volume in one second (FEV1) = 60 % of Predicted Normal (PN) and post-bronchodilator FEV1 = 80 % PN 6. Patients treated with low stable dose of inhaled corticosteroid or leukotriene antagonist in addition to 'as needed' use of inhaled short-acting bronchodilator(s) should have pre-bronchodilator FEV1 =80 % PN 7. Patients should have reversible airway obstruction 8. To be randomized patients must have used Bricanyl Turbuhaler 'as needed' on at least 3 separate days during the last week of the run in period. EXCLUSION CRITERIA 1. Patient has a history of life-threatening asthma including intubation and intensive care unit admission 2. Patient has had an asthma worsening requiring change in treatment other than inhaled short-acting bronchodilator(s) within 30 days prior to Visit 1 or between Visits 1 and 2; or a treatment other than Bricanyl Turbuhaler from Visit 2 until randomization 3. Patient has required treatment with oral, rectal or parenteral glucocorticosteroids (GCS) within 30 days and/or depot parenteral GCS within 12 weeks prior to Visit 1 4. Smoker (current or previous) with a smoking history of = 10 pack years 5. Pregnancy, breast-feeding or planned pregnancy during the study.
Query!
Minimum age
12
Years
Query!
Query!
Maximum age
130
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
7/07/2014
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
2/08/2017
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
3850
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment hospital [1]
0
0
Research Site - Bedford Park
Query!
Recruitment hospital [2]
0
0
Research Site - Concord
Query!
Recruitment hospital [3]
0
0
Research Site - Maroubra
Query!
Recruitment hospital [4]
0
0
Research Site - Murdoch
Query!
Recruitment hospital [5]
0
0
Research Site - Wollongong
Query!
Recruitment postcode(s) [1]
0
0
5042 - Bedford Park
Query!
Recruitment postcode(s) [2]
0
0
2139 - Concord
Query!
Recruitment postcode(s) [3]
0
0
2035 - Maroubra
Query!
Recruitment postcode(s) [4]
0
0
6150 - Murdoch
Query!
Recruitment postcode(s) [5]
0
0
2522 - Wollongong
Query!
Recruitment outside Australia
Country [1]
0
0
Brazil
Query!
State/province [1]
0
0
Alphaville
Query!
Country [2]
0
0
Brazil
Query!
State/province [2]
0
0
Botucatu
Query!
Country [3]
0
0
Brazil
Query!
State/province [3]
0
0
Porto Alegre
Query!
Country [4]
0
0
Brazil
Query!
State/province [4]
0
0
Salvador
Query!
Country [5]
0
0
Brazil
Query!
State/province [5]
0
0
Santo Andre
Query!
Country [6]
0
0
Brazil
Query!
State/province [6]
0
0
Sao Paulo
Query!
Country [7]
0
0
Brazil
Query!
State/province [7]
0
0
Sorocaba
Query!
Country [8]
0
0
Bulgaria
Query!
State/province [8]
0
0
Dupnitsa
Query!
Country [9]
0
0
Bulgaria
Query!
State/province [9]
0
0
Gotse Delchev
Query!
Country [10]
0
0
Bulgaria
Query!
State/province [10]
0
0
Kozloduy
Query!
Country [11]
0
0
Bulgaria
Query!
State/province [11]
0
0
Pazardzhik
Query!
Country [12]
0
0
Bulgaria
Query!
State/province [12]
0
0
Plovdiv
Query!
Country [13]
0
0
Bulgaria
Query!
State/province [13]
0
0
Razgrad
Query!
Country [14]
0
0
Bulgaria
Query!
State/province [14]
0
0
Roman
Query!
Country [15]
0
0
Bulgaria
Query!
State/province [15]
0
0
Ruse
Query!
Country [16]
0
0
Bulgaria
Query!
State/province [16]
0
0
Sandanski
Query!
Country [17]
0
0
Bulgaria
Query!
State/province [17]
0
0
Sofia
Query!
Country [18]
0
0
Bulgaria
Query!
State/province [18]
0
0
Varna
Query!
Country [19]
0
0
Bulgaria
Query!
State/province [19]
0
0
Velingrad
Query!
Country [20]
0
0
Bulgaria
Query!
State/province [20]
0
0
Vratsa
Query!
Country [21]
0
0
Canada
Query!
State/province [21]
0
0
Alberta
Query!
Country [22]
0
0
Canada
Query!
State/province [22]
0
0
British Columbia
Query!
Country [23]
0
0
Canada
Query!
State/province [23]
0
0
Newfoundland and Labrador
Query!
Country [24]
0
0
Canada
Query!
State/province [24]
0
0
Ontario
Query!
Country [25]
0
0
Canada
Query!
State/province [25]
0
0
Quebec
Query!
Country [26]
0
0
Chile
Query!
State/province [26]
0
0
Quillota
Query!
Country [27]
0
0
Chile
Query!
State/province [27]
0
0
Santiago
Query!
Country [28]
0
0
Chile
Query!
State/province [28]
0
0
Talcahuano
Query!
Country [29]
0
0
China
Query!
State/province [29]
0
0
Beijing
Query!
Country [30]
0
0
China
Query!
State/province [30]
0
0
Changsha
Query!
Country [31]
0
0
China
Query!
State/province [31]
0
0
Chengdu
Query!
Country [32]
0
0
China
Query!
State/province [32]
0
0
Guangzhou
Query!
Country [33]
0
0
China
Query!
State/province [33]
0
0
Haikou
Query!
Country [34]
0
0
China
Query!
State/province [34]
0
0
Hohhot
Query!
Country [35]
0
0
China
Query!
State/province [35]
0
0
Nanchang
Query!
Country [36]
0
0
China
Query!
State/province [36]
0
0
Shanghai
Query!
Country [37]
0
0
China
Query!
State/province [37]
0
0
Shenyang
Query!
Country [38]
0
0
China
Query!
State/province [38]
0
0
Wenzhou
Query!
Country [39]
0
0
China
Query!
State/province [39]
0
0
Wuhan
Query!
Country [40]
0
0
China
Query!
State/province [40]
0
0
Xi'an
Query!
Country [41]
0
0
China
Query!
State/province [41]
0
0
Xiamen
Query!
Country [42]
0
0
China
Query!
State/province [42]
0
0
Xuzhou
Query!
Country [43]
0
0
Hungary
Query!
State/province [43]
0
0
Balassagyarmat
Query!
Country [44]
0
0
Hungary
Query!
State/province [44]
0
0
Berettyóújfalu
Query!
Country [45]
0
0
Hungary
Query!
State/province [45]
0
0
Budapest
Query!
Country [46]
0
0
Hungary
Query!
State/province [46]
0
0
Edelény
Query!
Country [47]
0
0
Hungary
Query!
State/province [47]
0
0
Hajdúnánás
Query!
Country [48]
0
0
Hungary
Query!
State/province [48]
0
0
Miskolc
Query!
Country [49]
0
0
Hungary
Query!
State/province [49]
0
0
Monor
Query!
Country [50]
0
0
Hungary
Query!
State/province [50]
0
0
Mátészalka
Query!
Country [51]
0
0
Hungary
Query!
State/province [51]
0
0
Nyírbátor
Query!
Country [52]
0
0
Hungary
Query!
State/province [52]
0
0
Nyíregyháza
Query!
Country [53]
0
0
Hungary
Query!
State/province [53]
0
0
Pécs
Query!
Country [54]
0
0
Hungary
Query!
State/province [54]
0
0
Szeged
Query!
Country [55]
0
0
Korea, Republic of
Query!
State/province [55]
0
0
Bucheon-si
Query!
Country [56]
0
0
Korea, Republic of
Query!
State/province [56]
0
0
Cheongju-si
Query!
Country [57]
0
0
Korea, Republic of
Query!
State/province [57]
0
0
Incheon
Query!
Country [58]
0
0
Korea, Republic of
Query!
State/province [58]
0
0
Seoul
Query!
Country [59]
0
0
Mexico
Query!
State/province [59]
0
0
D.f.
Query!
Country [60]
0
0
Mexico
Query!
State/province [60]
0
0
Durango
Query!
Country [61]
0
0
Mexico
Query!
State/province [61]
0
0
Mexico
Query!
Country [62]
0
0
Mexico
Query!
State/province [62]
0
0
Monterrey
Query!
Country [63]
0
0
Mexico
Query!
State/province [63]
0
0
Morelia
Query!
Country [64]
0
0
Mexico
Query!
State/province [64]
0
0
México
Query!
Country [65]
0
0
Mexico
Query!
State/province [65]
0
0
Villahermosa
Query!
Country [66]
0
0
Peru
Query!
State/province [66]
0
0
Cusco
Query!
Country [67]
0
0
Peru
Query!
State/province [67]
0
0
Lima
Query!
Country [68]
0
0
Peru
Query!
State/province [68]
0
0
Piura
Query!
Country [69]
0
0
Peru
Query!
State/province [69]
0
0
Surco
Query!
Country [70]
0
0
Philippines
Query!
State/province [70]
0
0
Lipa City
Query!
Country [71]
0
0
Philippines
Query!
State/province [71]
0
0
Manila
Query!
Country [72]
0
0
Philippines
Query!
State/province [72]
0
0
Pasig City
Query!
Country [73]
0
0
Philippines
Query!
State/province [73]
0
0
Quezon City
Query!
Country [74]
0
0
Poland
Query!
State/province [74]
0
0
Bialystok
Query!
Country [75]
0
0
Poland
Query!
State/province [75]
0
0
Elblag
Query!
Country [76]
0
0
Poland
Query!
State/province [76]
0
0
Grodzisk Mazowiecki
Query!
Country [77]
0
0
Poland
Query!
State/province [77]
0
0
Grudziadz
Query!
Country [78]
0
0
Poland
Query!
State/province [78]
0
0
Kielce
Query!
Country [79]
0
0
Poland
Query!
State/province [79]
0
0
Kraków
Query!
Country [80]
0
0
Poland
Query!
State/province [80]
0
0
Poznan
Query!
Country [81]
0
0
Poland
Query!
State/province [81]
0
0
Rzeszów
Query!
Country [82]
0
0
Poland
Query!
State/province [82]
0
0
Skierniewice
Query!
Country [83]
0
0
Poland
Query!
State/province [83]
0
0
Strzelce Opolskie
Query!
Country [84]
0
0
Poland
Query!
State/province [84]
0
0
Szczecin
Query!
Country [85]
0
0
Poland
Query!
State/province [85]
0
0
Slupca
Query!
Country [86]
0
0
Poland
Query!
State/province [86]
0
0
Tarnów
Query!
Country [87]
0
0
Poland
Query!
State/province [87]
0
0
Trzebnica
Query!
Country [88]
0
0
Poland
Query!
State/province [88]
0
0
Turek
Query!
Country [89]
0
0
Poland
Query!
State/province [89]
0
0
Zabrze
Query!
Country [90]
0
0
Poland
Query!
State/province [90]
0
0
Lódz
Query!
Country [91]
0
0
Romania
Query!
State/province [91]
0
0
Bragadiru
Query!
Country [92]
0
0
Romania
Query!
State/province [92]
0
0
Brasov
Query!
Country [93]
0
0
Romania
Query!
State/province [93]
0
0
Cluj-Napoca
Query!
Country [94]
0
0
Romania
Query!
State/province [94]
0
0
Constanta
Query!
Country [95]
0
0
Romania
Query!
State/province [95]
0
0
Pitesti
Query!
Country [96]
0
0
Romania
Query!
State/province [96]
0
0
Timisoara
Query!
Country [97]
0
0
Russian Federation
Query!
State/province [97]
0
0
Chelyabinsk
Query!
Country [98]
0
0
Russian Federation
Query!
State/province [98]
0
0
Ekaterinburg
Query!
Country [99]
0
0
Russian Federation
Query!
State/province [99]
0
0
Gatchina
Query!
Country [100]
0
0
Russian Federation
Query!
State/province [100]
0
0
Ivanovo
Query!
Country [101]
0
0
Russian Federation
Query!
State/province [101]
0
0
Kazan
Query!
Country [102]
0
0
Russian Federation
Query!
State/province [102]
0
0
Kemerovo
Query!
Country [103]
0
0
Russian Federation
Query!
State/province [103]
0
0
Krasnoyarsk
Query!
Country [104]
0
0
Russian Federation
Query!
State/province [104]
0
0
Moscow
Query!
Country [105]
0
0
Russian Federation
Query!
State/province [105]
0
0
Nizhny Novgorod
Query!
Country [106]
0
0
Russian Federation
Query!
State/province [106]
0
0
Novosibirsk
Query!
Country [107]
0
0
Russian Federation
Query!
State/province [107]
0
0
Penza
Query!
Country [108]
0
0
Russian Federation
Query!
State/province [108]
0
0
Perm
Query!
Country [109]
0
0
Russian Federation
Query!
State/province [109]
0
0
Petrozavodsk
Query!
Country [110]
0
0
Russian Federation
Query!
State/province [110]
0
0
Pyatigorsk
Query!
Country [111]
0
0
Russian Federation
Query!
State/province [111]
0
0
Ryazan
Query!
Country [112]
0
0
Russian Federation
Query!
State/province [112]
0
0
Saint - Petersburg
Query!
Country [113]
0
0
Russian Federation
Query!
State/province [113]
0
0
Saint Petersburg
Query!
Country [114]
0
0
Russian Federation
Query!
State/province [114]
0
0
Saint-Petersburg
Query!
Country [115]
0
0
Russian Federation
Query!
State/province [115]
0
0
Saratov
Query!
Country [116]
0
0
Russian Federation
Query!
State/province [116]
0
0
St. Petersburg
Query!
Country [117]
0
0
Russian Federation
Query!
State/province [117]
0
0
St.Petersburg
Query!
Country [118]
0
0
Russian Federation
Query!
State/province [118]
0
0
Ulyanovsk
Query!
Country [119]
0
0
Russian Federation
Query!
State/province [119]
0
0
Vladikavkaz
Query!
Country [120]
0
0
Russian Federation
Query!
State/province [120]
0
0
Volgograd
Query!
Country [121]
0
0
Russian Federation
Query!
State/province [121]
0
0
Voronezh
Query!
Country [122]
0
0
Russian Federation
Query!
State/province [122]
0
0
Yaroslavl
Query!
Country [123]
0
0
South Africa
Query!
State/province [123]
0
0
Boksburg North
Query!
Country [124]
0
0
South Africa
Query!
State/province [124]
0
0
Durban
Query!
Country [125]
0
0
South Africa
Query!
State/province [125]
0
0
Johannesburg
Query!
Country [126]
0
0
South Africa
Query!
State/province [126]
0
0
Middelburg
Query!
Country [127]
0
0
South Africa
Query!
State/province [127]
0
0
Queenswood
Query!
Country [128]
0
0
South Africa
Query!
State/province [128]
0
0
Stanger
Query!
Country [129]
0
0
South Africa
Query!
State/province [129]
0
0
Verulam
Query!
Country [130]
0
0
Ukraine
Query!
State/province [130]
0
0
Cherkasy
Query!
Country [131]
0
0
Ukraine
Query!
State/province [131]
0
0
Dnipropetrovsk
Query!
Country [132]
0
0
Ukraine
Query!
State/province [132]
0
0
Ivano-Frankivsk
Query!
Country [133]
0
0
Ukraine
Query!
State/province [133]
0
0
Kharkiv
Query!
Country [134]
0
0
Ukraine
Query!
State/province [134]
0
0
Kyiv
Query!
Country [135]
0
0
Ukraine
Query!
State/province [135]
0
0
Lutsk
Query!
Country [136]
0
0
Ukraine
Query!
State/province [136]
0
0
Lviv
Query!
Country [137]
0
0
Ukraine
Query!
State/province [137]
0
0
Odesa
Query!
Country [138]
0
0
Ukraine
Query!
State/province [138]
0
0
Vinnytsia
Query!
Country [139]
0
0
Ukraine
Query!
State/province [139]
0
0
Zaporizhzhya
Query!
Country [140]
0
0
United Kingdom
Query!
State/province [140]
0
0
Bath
Query!
Country [141]
0
0
United Kingdom
Query!
State/province [141]
0
0
Coventry
Query!
Country [142]
0
0
United Kingdom
Query!
State/province [142]
0
0
Leamington Spa
Query!
Country [143]
0
0
United Kingdom
Query!
State/province [143]
0
0
Mortimer Reading
Query!
Country [144]
0
0
United Kingdom
Query!
State/province [144]
0
0
Trowbridge
Query!
Country [145]
0
0
Vietnam
Query!
State/province [145]
0
0
Dong Nai
Query!
Country [146]
0
0
Vietnam
Query!
State/province [146]
0
0
Hai Phong
Query!
Country [147]
0
0
Vietnam
Query!
State/province [147]
0
0
Hanoi
Query!
Country [148]
0
0
Vietnam
Query!
State/province [148]
0
0
Ho Chi Minh
Query!
Country [149]
0
0
Vietnam
Query!
State/province [149]
0
0
Hochiminh
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
AstraZeneca
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of this study is to test if Symbicort® (budesonide/formoterol) Turbuhaler® is effective in treating asthma when used 'as needed' in patients with milder asthma. The efficacy of Symbicort® 'as needed' will be compared with: 1) terbutaline Turbuhaler® 'as needed' and with 2) Pulmicort (budesonide) Turbuhaler® twice daily plus terbutaline Turbuhaler® 'as needed'.
Query!
Trial website
https://clinicaltrials.gov/study/NCT02149199
Query!
Trial related presentations / publications
FitzGerald JM, O'Byrne PM, Bateman ED, Barnes PJ, Zheng J, Ivanov S, Lamarca R, Larsdotter U, Emerath U, Jansen G, Puu M, Alagappan VKT, Surmont F, Reddel HK. Safety of As-Needed Budesonide-Formoterol in Mild Asthma: Data from the Two Phase III SYGMA Studies. Drug Saf. 2021 Apr;44(4):467-478. doi: 10.1007/s40264-020-01041-z. Epub 2021 Feb 6. O'Byrne PM, FitzGerald JM, Bateman ED, Barnes PJ, Zheng J, Gustafson P, Lamarca R, Puu M, Keen C, Alagappan VKT, Reddel HK. Effect of a single day of increased as-needed budesonide-formoterol use on short-term risk of severe exacerbations in patients with mild asthma: a post-hoc analysis of the SYGMA 1 study. Lancet Respir Med. 2021 Feb;9(2):149-158. doi: 10.1016/S2213-2600(20)30416-1. Epub 2020 Oct 1. O'Byrne PM, FitzGerald JM, Bateman ED, Barnes PJ, Zhong N, Keen C, Jorup C, Lamarca R, Ivanov S, Reddel HK. Inhaled Combined Budesonide-Formoterol as Needed in Mild Asthma. N Engl J Med. 2018 May 17;378(20):1865-1876. doi: 10.1056/NEJMoa1715274. O'Byrne PM, FitzGerald JM, Zhong N, Bateman E, Barnes PJ, Keen C, Almqvist G, Pemberton K, Jorup C, Ivanov S, Reddel HK. The SYGMA programme of phase 3 trials to evaluate the efficacy and safety of budesonide/formoterol given 'as needed' in mild asthma: study protocols for two randomised controlled trials. Trials. 2017 Jan 10;18(1):12. doi: 10.1186/s13063-016-1731-4. Reddel HK, Busse WW, Pedersen S, Tan WC, Chen YZ, Jorup C, Lythgoe D, O'Byrne PM. Should recommendations about starting inhaled corticosteroid treatment for mild asthma be based on symptom frequency: a post-hoc efficacy analysis of the START study. Lancet. 2017 Jan 14;389(10065):157-166. doi: 10.1016/S0140-6736(16)31399-X. Epub 2016 Nov 30.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Paul M O'Byrne, MB, FRCP(C), FRSC
Query!
Address
0
0
McMaster University, Hamilton, Canada
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Type
Other Details
Attachment
Statistical analysis plan
https://cdn.clinicaltrials.gov/large-docs/99/NCT02149199/SAP_000.pdf
Study protocol
https://cdn.clinicaltrials.gov/large-docs/99/NCT02149199/Prot_002.pdf
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results are available at
https://clinicaltrials.gov/study/NCT02149199
Download to PDF